www.MetabolicCareToday.com

The unique signature of tyrosine kinase inhibitor-induced hypothyroidism Tyrosine kinase inhibitors (TKIs) are anti-cancer agents that inhibit the activity of oncogenic protein kinases. Thyroid hormone abnormalities are common during treatment with TKIs, typically manifest...

The combined action of tyrosine kinase inhibitors (#TKIs) on #thyroid gland function & peripheral deiodinases generates a unique phenotype of primary #hypothyroidism characterised by increased TSH concentrations & a reduced T3 to T4 ratio www.thelancet.com/journals/lan...

#MedSky #EndoSky #OncSky

Obesity Guidelines in Focus: Defining Disease and Clinical Boundaries | Docwire News Beverly Tchang, MD, compares Canadian Obesity guidelines with the Lancet Commission on defining and treating obesity.

Canadian Obesity guidelines vs. the Lancet Commission:
Beverly Tchang, MD, unpacks differences in defining and treating obesity.

🎥 Watch here: www.docwirenews.com/post/obesity...

Orforglipron Phase 3 Data: Dr. Michael Weintraub Reviews ATTAIN-1 and ACHIEVE-1 Findings | Docwire News Dr. Michael Weintraub reviews phase 3 ATTAIN-1 and ACHIEVE-1 data on orforglipron in obesity and type 2 diabetes.

📊 mweintraubmd.bsky.social reviews ATTAIN-1 & ACHIEVE-1: oral GLP-1 #orforglipron shows weight loss & CV benefit but falls short of injectables. Caution urged on efficacy. @nyulangone.bsky.social

🔗 www.docwirenews.com/post/orforgl...

Balancing Benefits and GI Risks: What Clinicians Should Know About GLP-1 RAs | Docwire News Dr. Cho Han Chiang reviews GI risks of GLP-1 RAs, balancing safety with their metabolic and cardiovascular benefits.

GLP-1 RAs: Big benefits, small GI risks.
📊 +2 cholelithiasis & +4 GERD cases per 1,000 patients.
No rise in pancreatitis or bowel obstruction.
Dr. Cho Han Chiang explains how to weigh the trade-offs.
🎥 Watch here: www.docwirenews.com/post/balanci...

Targeting LONP1 to Protect Beta Cells: A New Therapeutic Avenue in Type 2 Diabetes | Docwire News Study finds mitochondrial protein misfolding drives beta cell failure in T2D, making LONP1 a potential therapy target.

New research out of @soleimanpourlab.bsky.social links beta cell failure in T2D to mitochondrial—not ER—protein misfolding. Boosting LONP1 protected cells & restored insulin function, pointing to a novel therapeutic path.

🎥 Watch: www.docwirenews.com/post/targeti...

🚨 New GLP-1 pill shows big results:
@elilillyandcompany.bsky.social's once-daily oral #orforglipron led to up to 27.3 lbs weight loss in 72 weeks in phase 3 #ATTAIN1, with improvements in heart risk markers. A potential game-changer for obesity care.
docwirenews.com/post/lillys-...
#Obesity #GLP1

Once Weekly Semaglutide Injection Trial Shows Favorable Results in Management of Type I Diabetes and | Docwire News Once-weekly semaglutide improved weight, insulin needs, and glycemic control in adults with T1D and obesity.

🚨 Once-weekly semaglutide led to major weight loss & improved glucose control in adults with #T1D + obesity—without added risk.
✅ -8.8 kg weight
✅ ↑ time-in-range
✅ No ↑ in severe hypo or DKA

Big step forward in #T1D care.
🔗 www.docwirenews.com/post/once-we...
#diabetes #GLP1 #semaglutide @nejm.org